Additionally, glutamate modulators, like ceftriaxone, can alleviate depression symptoms by inhibiting neuroinflammation via the GLT-1/TrkB signaling pathway (Gao et al., 2024). Here, SLC1A2 is linked to depressive symptom measurement.